Several preclinical studies have demonstrated the potential of NKG2D CAR-engineered T cells or NK cells to recruit and boost endogenous anti-tumor immune cells, prevent tumor neovasculature, and target myeloid-derived suppressor cells or regulatory T cells, thereby ameliorating the inhibitive TME (28–32). The gene discussed is KLRK1; the disease is neoplasm.